September 1, 2011

GeoVax grant increased to $4.4 million

Filed under: Regional Venture News — admin @ 4:00 pm

ATLANTA, GA -GeoVax Labs Inc. ’s recent $3.6 million Integrated Preclinical/Clinical AIDS Vaccine Development grant has been boosted to $4.4 million.

The grant was first awarded in 2007 to Atlanta-based GeoVax by the National Institutes of Health-National Institute of Allergy & Infectious Disease, an agency of the U.S. government. With the latest funding, the program has given GeoVax $20.4 million over the past five years.

“This award is important for the advancement of our GM-CSF adjuvanted vaccine that is achieving unprecedented levels of prevention of infection,” said Harriet Robinson, chief scientific officer of GeoVax and program director for the award. “When we started this project, I thought we could only control, not prevent, infections. It is truly wonderful to be achieving high levels of prevention of infection, and we are working very hard to move the vaccine through the needed efficacy trials for human use.”

GeoVax (OTC BB: GOVX) recently reported a net loss of $211,000 for the second quarter.

http://www.bizjournals.com/atlanta/news/2011/09/01/geovax-grant-increased-to-44-million.html?ed=2011-09-01&s=article_du&ana=e_du_pap

No Comments »

No comments yet.

RSS feed for comments on this post. TrackBack URL

Leave a comment